Zacks Investment Management Heron Therapeutics, Inc. Transaction History
Zacks Investment Management
- $11.4 Billion
- Q3 2024
A detailed history of Zacks Investment Management transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Zacks Investment Management holds 475,575 shares of HRTX stock, worth $532,644. This represents 0.01% of its overall portfolio holdings.
Number of Shares
475,575
Previous 464,255
2.44%
Holding current value
$532,644
Previous $1.62 Million
41.75%
% of portfolio
0.01%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding HRTX
# of Institutions
180Shares Held
121MCall Options Held
80.4KPut Options Held
94.9K-
Rubric Capital Management LP New York, NY26.7MShares$29.9 Million1.48% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.85MShares$9.91 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.72MShares$9.77 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.33MShares$9.32 Million0.0% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA6.99MShares$7.83 Million28.8% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $133M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...